Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 323

1.

Sunscreen bans: Coral reefs and skin cancer.

Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Kitzen JM; NEMA Research Group.

J Clin Pharm Ther. 2018 Nov 28. doi: 10.1111/jcpt.12778. [Epub ahead of print]

PMID:
30484882
2.

Does 'Strong Analgesic' Equal 'Strong Opioid'? Tapentadol and the Concept of 'µ-Load'.

Raffa RB, Elling C, Tzschentke TM.

Adv Ther. 2018 Sep 11. doi: 10.1007/s12325-018-0778-x. [Epub ahead of print]

3.

Designing safer analgesics: a focus on μ-opioid receptor pathways.

Pergolizzi JV Jr, LeQuang JA, Taylor R Jr, Ossipov MH, Colucci D, Raffa RB.

Expert Opin Drug Discov. 2018 Oct;13(10):965-972. doi: 10.1080/17460441.2018.1511539. Epub 2018 Sep 3.

PMID:
30175624
4.

Discovery of "folded DNA" structures in human cells: Potential drug targets.

Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Ossipov MH; NEMA Research Group.

J Clin Pharm Ther. 2018 Aug 25. doi: 10.1111/jcpt.12758. [Epub ahead of print]

PMID:
30144395
5.

What's holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholders.

Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Raffa RB.

Expert Opin Drug Deliv. 2018 Jun;15(6):567-576. doi: 10.1080/17425247.2018.1473374. Epub 2018 May 16.

PMID:
29739241
6.

Curcumin in turmeric: Basic and clinical evidence for a potential role in analgesia.

Eke-Okoro UJ, Raffa RB, Pergolizzi JV Jr, Breve F, Taylor R Jr; NEMA Research Group.

J Clin Pharm Ther. 2018 Aug;43(4):460-466. doi: 10.1111/jcpt.12703. Epub 2018 May 2. Review.

PMID:
29722036
7.

Indirect-acting strategy of opioid action instead of direct receptor activation: dual-acting enkephalinase inhibitors (DENKIs).

Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Ossipov MH; By the NEMA Research Group.

J Clin Pharm Ther. 2018 Aug;43(4):443-449. doi: 10.1111/jcpt.12687. Epub 2018 May 2. Review.

PMID:
29722031
8.

Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain.

Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Raffa RB, Bisney J.

Pain Ther. 2018 Jun;7(1):37-57. doi: 10.1007/s40122-018-0095-8. Epub 2018 Apr 5. Review.

9.

The role and mechanism of action of menthol in topical analgesic products.

Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Raffa RB; NEMA Research Group.

J Clin Pharm Ther. 2018 Jun;43(3):313-319. doi: 10.1111/jcpt.12679. Epub 2018 Mar 10. Review.

PMID:
29524352
10.

Nature's first "atypical opioids": Kratom and mitragynines.

Raffa RB, Pergolizzi JV, Taylor R, Ossipov MH; NEMA Research Group.

J Clin Pharm Ther. 2018 Jun;43(3):437-441. doi: 10.1111/jcpt.12676. Epub 2018 Mar 8.

PMID:
29520812
11.

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product.

Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Raffa RB.

J Pain Res. 2018 Feb 8;11:301-311. doi: 10.2147/JPR.S127602. eCollection 2018. Review.

12.

The role of cannabinoids in pain control: the good, the bad, and the ugly.

Pergolizzi JV Jr, Lequang JA, Taylor R Jr, Raffa RB, Colucci D; NEMA Research Group.

Minerva Anestesiol. 2018 Aug;84(8):955-969. doi: 10.23736/S0375-9393.18.12287-5. Epub 2018 Jan 16.

13.

Abuse-deterrent opioids: an update on current approaches and considerations.

Pergolizzi JV Jr, Raffa RB, Taylor R Jr, Vacalis S.

Curr Med Res Opin. 2018 Apr;34(4):711-723. doi: 10.1080/03007995.2017.1419171. Epub 2018 Jan 10.

PMID:
29262730
14.

Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects.

Raffa RB, Pawasauskas J, Pergolizzi JV Jr, Lu L, Chen Y, Wu S, Jarrett B, Fain R, Hill L, Devarakonda K.

Clin Drug Investig. 2018 Mar;38(3):259-268. doi: 10.1007/s40261-017-0610-4.

15.

Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin.

Pergolizzi JV Jr, LeQuang JA, Taylor R Jr, Raffa RB; NEMA Research Group.

Postgrad Med. 2018 Jan;130(1):1-8. doi: 10.1080/00325481.2018.1407618. Epub 2017 Nov 30. Review.

PMID:
29190175
16.

The rapid-onset antidepressant effect of ketamine: More surprises?

Raffa RB, Pergolizzi JV Jr, Taylor R Jr; NEMA Research Group.

J Clin Pharm Ther. 2018 Apr;43(2):308-311. doi: 10.1111/jcpt.12656. Epub 2017 Nov 26.

PMID:
29178131
17.

The fentanyl family: A distinguished medical history tainted by abuse.

Raffa RB, Pergolizzi JV Jr, LeQuang JA, Taylor R Jr; NEMA Research Group, Colucci S, Annabi MH.

J Clin Pharm Ther. 2018 Feb;43(1):154-158. doi: 10.1111/jcpt.12640. Epub 2017 Oct 4.

PMID:
28980330
18.

The "Darknet": The new street for street drugs.

Pergolizzi JV Jr, LeQuang JA Ba, Taylor R Jr, Raffa RB; NEMA Research Group.

J Clin Pharm Ther. 2017 Dec;42(6):790-792. doi: 10.1111/jcpt.12628. Epub 2017 Sep 15.

PMID:
28921578
19.

The effects of food on opioid-induced nausea and vomiting and pharmacological parameters: a systematic review.

Raffa RB, Colucci R, Pergolizzi JV.

Postgrad Med. 2017 Sep;129(7):698-708. doi: 10.1080/00325481.2017.1345282. Epub 2017 Jul 14. Review.

PMID:
28635354
20.

Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system.

Silverman S, Raffa RB, Cataldo MJ, Kwarcinski M, Ripa SR.

J Pain Res. 2017 May 24;10:1255-1263. doi: 10.2147/JPR.S132595. eCollection 2017.

21.

Considering tapentadol as a first-line analgesic: 14 questions.

Pergolizzi JV Jr, Breve F, Taylor R Jr, Raffa RB, Strasburger SE, LeQuang JA.

Pain Manag. 2017 Jul;7(4):331-339. doi: 10.2217/pmt-2016-0063. Epub 2017 Apr 24.

PMID:
28434283
22.

The Basic Pharmacology of Opioids Informs the Opioid Discourse about Misuse and Abuse: A Review.

Pergolizzi JV Jr, LeQuang JA, Berger GK, Raffa RB.

Pain Ther. 2017 Jun;6(1):1-16. doi: 10.1007/s40122-017-0068-3. Epub 2017 Mar 24. Review.

23.

Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting.

Pergolizzi JV Jr, Taylor R, LeQuang JA, Zampogna G, Raffa RB.

Cancer Chemother Pharmacol. 2017 Mar;79(3):467-477. doi: 10.1007/s00280-017-3257-1. Epub 2017 Feb 24. Review.

PMID:
28235999
24.

Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy.

Pergolizzi JV Jr, Raffa RB, Pappagallo M, Fleischer C, Pergolizzi J 3rd, Zampogna G, Duval E, Hishmeh J, LeQuang JA, Taylor R Jr.

Patient Prefer Adherence. 2017 Jan 17;11:107-119. doi: 10.2147/PPA.S78042. eCollection 2017. Review.

25.

What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.

Strasburger SE, Bhimani PM, Kaabe JH, Krysiak JT, Nanchanatt DL, Nguyen TN, Pough KA, Prince TA, Ramsey NS, Savsani KH, Scandlen L, Cavaretta MJ, Raffa RB.

J Clin Pharm Ther. 2017 Apr;42(2):147-154. doi: 10.1111/jcpt.12497. Epub 2017 Jan 22. Review.

PMID:
28111761
26.

Long-term use of opioids in 210 officially registered patients with chronic noncancer pain in Taiwan: A cross-sectional study.

Lin TC, Ger LP, Pergolizzi JV Jr, Raffa RB, Wang JO, Ho ST.

J Formos Med Assoc. 2017 Apr;116(4):257-265. doi: 10.1016/j.jfma.2016.10.015. Epub 2016 Dec 23.

27.

Safety of buprenorphine transdermal system in the management of pain in older adults.

Pergolizzi JV, Raffa RB, Marcum Z, Colucci S, Ripa SR.

Postgrad Med. 2017 Jan;129(1):92-101. doi: 10.1080/00325481.2017.1270699. Epub 2016 Dec 26.

PMID:
27929709
28.

Management of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technology.

Pergolizzi JV Jr, Raffa RB, Fleischer C, Zampogna G, Taylor R Jr.

J Pain Res. 2016 Oct 31;9:909-916. eCollection 2016. Review.

29.

The Centers for Disease Control and Prevention opioid guidelines: potential for unintended consequences and will they be abused?

Pergolizzi JV Jr, Raffa RB, LeQuang JA.

J Clin Pharm Ther. 2016 Dec;41(6):592-593. doi: 10.1111/jcpt.12444. Epub 2016 Aug 31.

PMID:
27576604
30.

Cebranopadol: novel dual opioid/NOP receptor agonist analgesic.

Raffa RB, Burdge G, Gambrah J, Kinecki HE, Lin F, Lu B, Nguyen JT, Phan V, Ruan A, Sesay MA, Watkins TN.

J Clin Pharm Ther. 2017 Feb;42(1):8-17. doi: 10.1111/jcpt.12461. Epub 2016 Oct 24. Review.

PMID:
27778406
31.

Change Pain: Ever Evolving-An Update for 2016.

Pergolizzi JV, Paladini A, Varrassi G, Raffa RB.

Pain Ther. 2016 Dec;5(2):127-133. Epub 2016 Oct 14.

32.

Comments and Suggestions from Pain Specialists Regarding the CDC's Proposed Opioid Guidelines.

Pergolizzi JV Jr, Raffa RB, Zampogna G, Breve F, Colucci R, Schmidt WK, LeQuang JA.

Pain Pract. 2016 Sep;16(7):794-808. doi: 10.1111/papr.12475. No abstract available.

PMID:
27600924
33.

Application of human factors engineering (HFE) to the design of a naloxone auto-injector for the treatment of opioid emergencies.

Raffa RB, Taylor R Jr, Pergolizzi JV Jr, Nalamachu S, Edwards ES, Edwards ET.

Drug Deliv Transl Res. 2017 Feb;7(1):1-10. doi: 10.1007/s13346-016-0323-x.

34.

Knowledge, Attitude and Practice Survey of Prescribing Opioids for Chronic Noncancer Pain in Taiwan-Comparison of Pain and Non-Pain Physicians.

Lin TC, Ger LP, Pergolizzi JV Jr, Raffa RB, Wang JO, Ho ST.

Pain Med. 2016 Aug 22. pii: pnw189. [Epub ahead of print]

PMID:
27550948
35.

Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?

Albert-Vartanian A, Boyd MR, Hall AL, Morgado SJ, Nguyen E, Nguyen VP, Patel SP, Russo LJ, Shao AJ, Raffa RB.

J Clin Pharm Ther. 2016 Aug;41(4):371-82. doi: 10.1111/jcpt.12404. Epub 2016 Jun 1. Review.

PMID:
27245498
36.

Good clinical practice guide for opioids in pain management: the three Ts - titration (trial), tweaking (tailoring), transition (tapering).

Coluzzi F, Taylor R Jr, Pergolizzi JV Jr, Mattia C, Raffa RB.

Braz J Anesthesiol. 2016 May-Jun;66(3):310-7. doi: 10.1016/j.bjane.2014.09.005. Epub 2014 Nov 28.

37.

[Good clinical practice guide for opioids in pain management: the three Ts - titration (trial), tweaking (tailoring), transition (tapering)].

Coluzzi F, Taylor R Jr, Pergolizzi JV Jr, Mattia C, Raffa RB.

Rev Bras Anestesiol. 2016 May-Jun;66(3):310-7. doi: 10.1016/j.bjan.2016.02.008. Epub 2016 Mar 15. Portuguese.

38.

Evolution to low-dose NSAID therapy.

Pergolizzi JV Jr, Raffa RB, Nalamachu S, Taylor R Jr.

Pain Manag. 2016 Apr;6(2):175-89. doi: 10.2217/pmt.15.69. Epub 2016 Mar 16. Review.

PMID:
26980438
39.

A Guide for Pain Management in Low and Middle Income Communities. Managing the Risk of Opioid Abuse in Patients with Cancer Pain.

Pergolizzi JV, Zampogna G, Taylor R, Gonima E, Posada J, Raffa RB.

Front Pharmacol. 2016 Mar 1;7:42. doi: 10.3389/fphar.2016.00042. eCollection 2016. Review.

40.

Postoperative Pain Surveys in Italy from 2006 and 2012: (POPSI and POPSI-2).

Coluzzi F, Mattia C, Savoia G, Clemenzi P, Melotti R, Raffa RB, Pergolizzi JV Jr.

Eur Rev Med Pharmacol Sci. 2015 Nov;19(22):4261-9.

41.

The role of abuse-deterrent formulations in countering opioid misuse and abuse.

Nguyen V, Raffa RB, Taylor R, Pergolizzi JV Jr.

J Clin Pharm Ther. 2015 Dec;40(6):629-34. doi: 10.1111/jcpt.12337. Epub 2015 Nov 23. Review.

PMID:
26595258
42.

Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs.

Li Z, Pergolizzi JV, Huttner RP, Zampogna G, Breve F, Raffa RB.

J Clin Pharm Ther. 2015 Dec;40(6):615-9. doi: 10.1111/jcpt.12331. Epub 2015 Nov 17. Review.

PMID:
26573866
43.

Perspectives on Intravenous Oxycodone for Control of Postoperative Pain.

Pergolizzi JV Jr, Seow-Choen F, Wexner SD, Zampogna G, Raffa RB, Taylor R Jr.

Pain Pract. 2016 Sep;16(7):924-34. doi: 10.1111/papr.12345. Epub 2015 Sep 22. Review.

PMID:
26393529
44.

Is levorphanol a better option than methadone?

Pham TC, Fudin J, Raffa RB.

Pain Med. 2015 Sep;16(9):1673-9. doi: 10.1111/pme.12795. Epub 2015 Aug 26. Review.

PMID:
26307179
45.

Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease.

Coluzzi F, Raffa RB, Pergolizzi J, Rocco A, Locarini P, Cenfra N, Cimino G, Mattia C.

J Pain Res. 2015 May 8;8:229-38. doi: 10.2147/JPR.S83490. eCollection 2015.

46.

The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain.

Pergolizzi JV Jr, Taylor R Jr, Raffa RB.

Adv Ther. 2015 Jun;32(6):485-95. doi: 10.1007/s12325-015-0213-5. Epub 2015 May 31.

47.

Clostridium difficile infection: A brief update on emerging therapies.

Goldberg EJ, Bhalodia S, Jacob S, Patel H, Trinh KV, Varghese B, Yang J, Young SR, Raffa RB.

Am J Health Syst Pharm. 2015 Jun 15;72(12):1007-12. doi: 10.2146/ajhp140645. Review.

PMID:
26025991
48.

Acetaminophen (paracetamol) oral absorption and clinical influences.

Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Decker JF, Patrick JT.

Pain Pract. 2014 Sep;14(7):668-77. doi: 10.1111/papr.12130. Epub 2013 Oct 28. Review.

PMID:
26013309
49.

Maximizing value in opioid utilization: Is oxycodone immediate release a good option for pain management?

Pergolizzi JV, Köknel Talu G, Zmponga G, Erdine S, Taylor R, Ayan B, Raffa RB.

Agri. 2015;27(1):1-11. doi: 10.5505/agri.2015.79663. Review.

50.

The unsolved case of "bone-impairing analgesics": the endocrine effects of opioids on bone metabolism.

Coluzzi F, Pergolizzi J, Raffa RB, Mattia C.

Ther Clin Risk Manag. 2015 Mar 31;11:515-23. doi: 10.2147/TCRM.S79409. eCollection 2015.

Supplemental Content

Loading ...
Support Center